Scioto Biosciences, Inc. Announces Top-Line Results of SB-121 in a Phase Ib Trial in Patients Diagnosed With Autism Spectrum Disorder
This first-in-human study was a randomized, double-blind, placebo-controlled, 28-day daily-dose crossover study of the safety and tolerability of SB-121 (Lactobacillus reuteri with dextran microparticles and maltose) in patients, ages 15 to 45 years, diagnosed with autism spectrum disorder (ASD).
- This first-in-human study was a randomized, double-blind, placebo-controlled, 28-day daily-dose crossover study of the safety and tolerability of SB-121 (Lactobacillus reuteri with dextran microparticles and maltose) in patients, ages 15 to 45 years, diagnosed with autism spectrum disorder (ASD).
- The study was conducted at the Cincinnati Childrens Medical Center, with Craig Erickson, MD as the Principal Investigator.
- Dr. Erickson is Professor of Psychiatry and Director of Research at the Kelly O'Leary Center for Autism Spectrum Disorders and Division of Child and Adolescent Psychiatry at Cincinnati Childrens Hospital Medical Center.
- Top-line results from the study demonstrated that SB-121 was safe and well tolerated.